BACKGROUND: The natural evolution of signs and symptoms during acute heart failure (AHF) is poorly characterized. METHODS AND RESULTS: We followed a prospective international cohort of 182 patients hospitalized with AHF. Patient-reported dyspnea and general well-being (GWB) were measured daily using 7-tier Likert (-3 to +3) and visual analog scales (VAS, 0-100). Physician assessments were also recorded daily. Mean age was 69 years and 68% had ejection fraction <40%. Likert measures of dyspnea initially improved rapidly (day 1, 0.22; day 2, 1.31; P <.001) with no significant improvement thereafter (day 7, 1.51; day 2 versus 7 P = .16). In contrast, VAS measure of dyspnea improved throughout hospitalization (day 1, 50.1; day 2, 64.7; day 7, 83.2; day 1 versus 2 P < .001, day 2 versus 7 P < .001). Symptoms of dyspnea and GWB tracked closely (correlation r = .813, P < .001). Physical signs resolved more completely than did symptoms (eg, from day 1 to discharge/day 7, absence of edema increased from 33% to 72% of patients, whereas significant improvements in dyspnea increased from 27% to 52% of patients; P < .001). CONCLUSIONS: Changes in patient-reported symptoms and physician-assessed signs followed different patterns during an AHF episode and are influenced by the measurement scales used. Multiple clinical measures should be considered in discharge decisions and evaluation of AHF therapies.
BACKGROUND: The natural evolution of signs and symptoms during acute heart failure (AHF) is poorly characterized. METHODS AND RESULTS: We followed a prospective international cohort of 182 patients hospitalized with AHF. Patient-reported dyspnea and general well-being (GWB) were measured daily using 7-tier Likert (-3 to +3) and visual analog scales (VAS, 0-100). Physician assessments were also recorded daily. Mean age was 69 years and 68% had ejection fraction <40%. Likert measures of dyspnea initially improved rapidly (day 1, 0.22; day 2, 1.31; P <.001) with no significant improvement thereafter (day 7, 1.51; day 2 versus 7 P = .16). In contrast, VAS measure of dyspnea improved throughout hospitalization (day 1, 50.1; day 2, 64.7; day 7, 83.2; day 1 versus 2 P < .001, day 2 versus 7 P < .001). Symptoms of dyspnea and GWB tracked closely (correlation r = .813, P < .001). Physical signs resolved more completely than did symptoms (eg, from day 1 to discharge/day 7, absence of edema increased from 33% to 72% of patients, whereas significant improvements in dyspnea increased from 27% to 52% of patients; P < .001). CONCLUSIONS: Changes in patient-reported symptoms and physician-assessed signs followed different patterns during an AHF episode and are influenced by the measurement scales used. Multiple clinical measures should be considered in discharge decisions and evaluation of AHF therapies.
Authors: Peter A McCullough; Edward F Philbin; John A Spertus; Scott Kaatz; Keisha R Sandberg; W Douglas Weaver Journal: J Am Coll Cardiol Date: 2002-01-02 Impact factor: 24.094
Authors: Andrew J Burger; Darlene P Horton; Thierry LeJemtel; Jalal K Ghali; Guillermo Torre; George Dennish; Michael Koren; Jay Dinerman; Marc Silver; Mei L Cheng; Uri Elkayam Journal: Am Heart J Date: 2002-12 Impact factor: 4.749
Authors: Daniel Levy; Satish Kenchaiah; Martin G Larson; Emelia J Benjamin; Michelle J Kupka; Kalon K L Ho; Joanne M Murabito; Ramachandran S Vasan Journal: N Engl J Med Date: 2002-10-31 Impact factor: 91.245
Authors: Michael S Cuffe; Robert M Califf; Kirkwood F Adams; Raymond Benza; Robert Bourge; Wilson S Colucci; Barry M Massie; Christopher M O'Connor; Ileana Pina; Rebecca Quigg; Marc A Silver; Mihai Gheorghiade Journal: JAMA Date: 2002-03-27 Impact factor: 56.272
Authors: W S Colucci; U Elkayam; D P Horton; W T Abraham; R C Bourge; A D Johnson; L E Wagoner; M M Givertz; C S Liang; M Neibaur; W H Haught; T H LeJemtel Journal: N Engl J Med Date: 2000-07-27 Impact factor: 91.245
Authors: Chiara Melloni; Eric D Peterson; Anita Y Chen; Lynda A Szczech; L Kristin Newby; Robert A Harrington; W Brian Gibler; E Magnus Ohman; Sarah A Spinler; Matthew T Roe; Karen P Alexander Journal: J Am Coll Cardiol Date: 2008-03-11 Impact factor: 24.094
Authors: Michael M Givertz; Barry M Massie; Tara K Fields; Leeanne L Pearson; Howard C Dittrich Journal: J Am Coll Cardiol Date: 2007-10-01 Impact factor: 24.094
Authors: G Michael Felker; Kerry L Lee; David A Bull; Margaret M Redfield; Lynne W Stevenson; Steven R Goldsmith; Martin M LeWinter; Anita Deswal; Jean L Rouleau; Elizabeth O Ofili; Kevin J Anstrom; Adrian F Hernandez; Steven E McNulty; Eric J Velazquez; Abdallah G Kfoury; Horng H Chen; Michael M Givertz; Marc J Semigran; Bradley A Bart; Alice M Mascette; Eugene Braunwald; Christopher M O'Connor Journal: N Engl J Med Date: 2011-03-03 Impact factor: 91.245
Authors: Amirali Masoumi; Fernando Ortiz; Jai Radhakrishnan; Robert W Schrier; Paolo C Colombo Journal: Heart Fail Rev Date: 2015-05 Impact factor: 4.214
Authors: Horng H Chen; Omar F AbouEzzeddine; Kevin J Anstrom; Michael M Givertz; Bradley A Bart; G Michael Felker; Adrian F Hernandez; Kerry L Lee; Eugene Braunwald; Margaret M Redfield Journal: Circ Heart Fail Date: 2013-09-01 Impact factor: 8.790
Authors: Marco Metra; John R Teerlink; G Michael Felker; Barry H Greenberg; Gerasimos Filippatos; Piotr Ponikowski; Sam L Teichman; Elaine Unemori; Adriaan A Voors; Beth Davison Weatherley; Gad Cotter Journal: Eur J Heart Fail Date: 2010-08-22 Impact factor: 15.534
Authors: Peter S Pang; Sean P Collins; Kori Sauser; Adin-Cristian Andrei; Alan B Storrow; Judd E Hollander; Miguel Tavares; Jindrich Spinar; Cezar Macarie; Dimitar Raev; Richard Nowak; Mihai Gheorghiade; Alexandre Mebazaa Journal: Acad Emerg Med Date: 2014-06 Impact factor: 3.451